The Board of Directors of Ipca Laboratories will convene on Thursday, November 13, 2025, to review and approve the standalone and consolidated unaudited financial results for the second quarter (Q2: July-September) and half-year ended September 30, 2025. A trading window restriction is currently in effect and will continue until 48 hours after the results are declared, with an expected end date of November 15, 2025.
Board Meeting Announcement
Ipca Laboratories has announced that a meeting of its Board of Directors is scheduled for Thursday, November 13, 2025. The primary purpose of this meeting is to consider and approve the company’s unaudited financial results.
Financial Results on the Agenda
During the meeting, the Board will review both the standalone and consolidated unaudited financial results for the second quarter (Q2: July-September) and half-year period, both ending on September 30, 2025. This includes a detailed analysis of the company’s financial performance during this period.
Trading Window Closure
In accordance with regulatory requirements, the trading window for company insiders is currently closed. This restriction began after September 22, 2025, and will remain in effect until 48 hours after the declaration of the financial results. Therefore, trading is expected to resume on November 15, 2025.
Source: BSE
